Long-term Management of Patients With Ruptured HCC

University Hospital, Caen112 enrolled

Overview

The main objective of this work is to evaluate the prevalence and results of specific management of HCC after spontaneous rupture, since the arrival of sorafenib in 2008.

Retrospective, observational, multicenter study over the period from January 2008 to April 2024. Cases had to be 18 years or older. They were identified by two different methodologies adapted to the 4 participating centers. In particular, a request for ICD10 C22.0 (CHC) codes associated with K66.1 (hemoperitoneum) was carried out by the medical information departments (DIM) of the Caen University Hospital and the Avicenne hospital. Secondly, the automated keyword selection tools "Cohort 360" and "i2b2" were used at the La Pitié Salpetrière and Paul Brousse hospital centers to identify the terms "CHC" and "ruptured" in the computerized patient files. Secondarily, duplicates and coding errors were excluded.

Study Type

OBSERVATIONAL

Enrollment

112

Conditions

Hepatocellular Carcinoma

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Ruptured hepatocellular carcinoma with or without cirrhosis Exclusion Criteria: * Liver adenoma without histologically proven HCC * Other benign or malignant liver tumors * ATCD of potentially triggering interventional procedure in the previous month. * Hemorrhagic ascites without tumor * Intratumoral hemorrhages without hemoperitoneum or capsular rupture

Outcomes

Primary Outcomes

Survival after rupture of hepatocellular carcinoma

Time frame: 15 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.